Major Growth Boosting Factors:
The apheresis market is primarily driven by the rising prevalence of chronic diseases and the growing number of trauma and injury cases, the increasing demand for source plasma from biopharmaceutical companies, the rising demand for blood components and growing concerns regarding blood safety, the increase in the number of complex surgical procedures, and the favorable reimbursement for apheresis procedures.
However, the high cost of apheresis devices & therapeutic apheresis procedures and installation of apheresis devices through the rental model, fewer blood donations using apheresis due to lack of awareness, and the stringent donor recruitment criteria are factors expected to limit market growth to a certain extent in the coming years.
Expected Revenue Surge Globally:
The global apheresis market is expected to reach USD 2.7 billion by 2025 from an estimated value of USD 1.7 billion in 2019, growing at a CAGR of 8.1% during the forecast period.
Recent Developments:
# In July 2019, Baxter International Inc. (US) launched the PrisMax system in the US.
# In June 2019, Toray Medical Co. Ltd. (Japan) launched the TORAMYXIN device in the European region.
# In October 2019, Terumo BCT (US) collaborated with the UniCAR-Therapy Bio-Medicine Technology Co. (China). This collaboration aimed at advancing CAR T-cell therapies by creating a new Shanghai Center of Excellence. This development also helped Terumo widen its applications of apheresis and leukapheresis procedures.
# In August 2017, Fresenius Medical Care (Germany) acquired NxStage Medical, Inc. (US). This acquisition enabled Fresenius Medical Care to further expand its presence in the renal care and critical care area.
The centrifugal apheresis devices segment is projected to grow at the highest CAGR during the forecast period
Based on the type of apheresis devices, the market is segmented into centrifugal apheresis devices and membrane separation devices. The centrifugal apheresis devices segment is expected to grow at the highest rate during the forecast period. Factors such as advantages offered by centrifugation over membrane separation and the higher efficiency of centrifugation with the ability to separate all types of blood components are propelling the growth of the centrifugal apheresis devices market.
Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=950
The therapeutic apheresis segment is projected to grow at the highest CAGR during the forecast period
On the basis of procedure, the apheresis market is segmented into automated blood collection (donor apheresis) and therapeutic apheresis. The therapeutic apheresis segment is expected to grow at the highest rate during the forecast period. Growth in this segment can be attributed to the increasing adoption of apheresis procedures for the treatment of various neurological, blood, and renal diseases, the increasing prevalence of blood disorders, and favorable reimbursement policies for apheresis procedures.
The photopheresis segment is projected to grow at the highest CAGR during the forecast period
On the basis of application, the apheresis market is segmented into plasmapheresis, plateletpheresis, erythrocytapheresis, leukapheresis, photopheresis, and other applications. The photopheresis segment is expected to grow at the highest rate during the forecast period. Growth in this segment can be attributed to the increasing prevalence of blood disorders and the rising demand for photopheresis in organ transplant rejection treatments.
Key Players:
The key players in the global apheresis market are Terumo BCT, Inc. (US), Fresenius SE & Co. KGaA (Germany), Haemonetics Corporation (US), Asahi Kasei Medical Co. Ltd. (Japan), B. Braun Melsungen AG (Germany), Baxter International Inc. (US), Cerus Corporation (US), Kaneka Corporation (Japan), Kawasumi Laboratories, Inc. (Japan), and Nikkiso Co., Ltd. (Japan).
In 2018, the blood collection centers and blood component providers segment accounted for the largest share of the market
Based on end users, the apheresis market is segmented into blood collection centers and blood component providers, hospitals and transfusion centers, and other end users. In 2018, the blood collection centers and blood component providers segment accounted for the largest share of 67.5% of the global apheresis market. The large share of this end-user segment is mainly attributed to the rising number of blood component donations, a growing number of blood centers, and increasing awareness of blood collection.
North America accounted for the largest share of the apheresis market in 2018
The apheresis market is segmented into five major regions, namely, North America, Europe, the Asia Pacific (APAC), Latin America, and the Middle East & Africa. In 2018, North America accounted for the largest share of the apheresis market. The large share of this region can be attributed to easier access to advanced blood collection technologies, the presence of established healthcare infrastructure, and the increasing presence of leading apheresis companies in the country.
Download PDF Brochure@
No comments:
Post a Comment